Day: January 8, 2021

The Supervisory Board of AS LHV Finance, Belonging to AS LHV Group consolidation group, plans to elect Mari-Liis Stalde to be the new Member of the Management Board of the company. At the same time, shareholders of the the company plan to elect Kadri Kiisel the new Member and Chairman of the Supervisory Board of AS LHV Finance in the place of Erki Kilu.LHV Finance is dealing in hire-purchase and gives out small loans. The Management Board of the company has one member. In addition to Kadri Kiisel the other Members of the Supervisory Board of AS LHV Finance include Madis Toomsalu, Jaan Koppel and Veiko Poolgas.Mari-Liis Stalde has worked as the business line manager of business clients’ everyday banking at Coop Pank since 2017. In 2010-2016 she was a business client manager at LHV Pank and in 2005-2010 worked at Nordea Pank. In 2005 Stalde...

AS-i LHV Group konsolideerimisgruppi kuuluva ettevõtte AS-i LHV Finance nõukogu plaanib alates 29.01.2021 valida ettevõtte uueks juhatuse liikmeks Mari-Liis Stalde. Ühtlasi plaanivad ettevõtte aktsionärid valida AS-i LHV Finance nõukogu uueks liikmeks ja esimeheks Kadri Kiiseli senise esimehe Erki Kilu asemel.LHV Finance tegeleb järelmaksu ja väikelaenu pakkumisega. Ettevõtte juhatusse kuulub üks liige. Lisaks Kadri Kiiselile kuuluvad AS-i LHV Finance nõukokku Madis Toomsalu, Jaan Koppel ja Veiko Poolgas.Mari-Liis Stalde töötas aastast 2017 Coop Panga äriklientide igapäevapanganduse äriliini juhina. Aastatel 2010–2016 töötas ta LHV Pangas ärikliendihaldurina ning aastatel 2005–2010 Nordea Pangas. Stalde on lõpetanud 2005. aastal bakalaureuseõppe Eesti Maaülikoolis raamatupidamise erialal ning õppinud Tallinna Tehnikaülikoolis ärirahandust...

REGULATED INFORMATIONPreliminary documents for the Extraordinary General Meeting have been made available on company’s websiteGosselies, Belgium, 8 January 2021, 7am CET – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and other diseases, informs its shareholders and holders of warrants and convertible bonds of the Company that an extraordinary general shareholders’ meeting will be held on Monday 8 February 2021 at 10am CET, at the Company’s registered offices, rue Auguste Piccard 37, 6041 Gosselies, Belgium. If the attendance quorum is not reached at this extraordinary shareholders’ meeting, a second shareholders’ meeting will be convened and held on 26 February 2021 as of 10am CET, at rue Auguste Piccard 37, 6041 Gosselies.The notice for the meeting, including...

INFORMATION RÉGLEMENTÉEMise à disposition des documents préparatoires à l’Assemblée générale extraordinaire sur le site internet de la SociétéGosselies, Belgique, le 8 janvier 2021 à 7h00 CET – BONE THERAPEUTICS (Euronext Bruxelles et Paris : BOTHE), société de biotechnologie spécialisée dans le développement de thérapies cellulaires innovantes répondant aux besoins médicaux non satisfaits en l’orthopédie et dans d’autres pathologies graves, informe ses actionnaires et les détenteurs de warrants et d’obligations convertibles de la Société qu’une assemblée générale extraordinaire se tiendra le lundi 8 février 2021 à 10h00 CET au siège social de la société, rue Auguste Piccard 37, 6041 Gosselies, Belgique. Si le quorum de présence pour l’assemblée générale extraordinaire n’est pas atteint, une seconde assemblée générale...

Submitted Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) for efgartigimod in generalized myasthenia gravis (gMG)Initiated 50-patient gMG bridging study of subcutaneous (SC) efgartigimod based on FDA feedbackEnrolled first 30 patients, necessary for go/no-go decision, in ADHERE trial of SC efgartigimod for chronic inflammatory demyelinating polyneuropathy (CIDP)Announced interim data from Phase 2 CULMINATE trial of cusatuzumab in development with JanssenBreda, the Netherlands – Jan. 8, 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced its 2021 corporate priorities and highlighted recent achievements from its late-stage immunology pipeline driven by its FcRn antagonist,...

Preliminary Q420 net revenues of $3.24 billion, above the outlook rangeQ4&FY20 earnings release date: Thursday January 28, 2021Geneva – January 8, 2021 – STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, announced today that its preliminary and unaudited net revenues for the fourth quarter ended December 31, 2020 are above the business outlook range provided in the Company’s news release dated October 22, 2020.Preliminary Q420 net revenues are $3.24 billion, up 21.3% sequentially and 580 basis points above the high end of the range. The prior outlook was for Q420 net revenues to be $2.99 billion, an increase of 12.0% sequentially, plus or minus 350 basis points.“We ended Q420 with net revenues above the outlook range due to significantly better than expected...

Chiffre d’affaires net préliminaire du 4ème trimestre 2020 de 3,24 milliards de dollars, au-dessus de la fourchette de prévisionsDate de publication des résultats financiers du 4ème trimestre et de l’année 2020 : jeudi 28 janvier 2021Genève, le 8 janvier 2021 – STMicroelectronics (NYSE : STM),

Revenue organic growth at -22.7%, and -21.5% excluding Rugby World Cup base effect

Croissance interne du chiffre d’affaires à – 22,7 % et – 21,5 % hors effet de la Coupe du Monde de Rugby

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — Please note that the embedded hyperlinks in the press release below have been corrected from a release issued under the same headline earlier today.Cullinan Management, Inc., a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, announced today the pricing of its upsized initial public offering of 11,900,000 shares of common stock at a price to the public of $21.00 per share. All shares are being offered by Cullinan Management. The gross proceeds to Cullinan Management from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $249.9 million. In addition, the underwriters have a 30-day...